MARKETS

BSE Prices delayed by 5 minutes... Prices as on Feb 23, 2018   ABB India 1521.95 [ 0.73% ]ACC 1646.8 [ 0.94% ]Ambuja Cements Ltd. 259.7 [ 1.11% ]Asian Paints Ltd. 1101.9 [ -1.29% ]Axis Bank Ltd. 536.55 [ 1.24% ]Bajaj Auto Ltd. 2988 [ 0.57% ]Bank of Baroda 145.6 [ 1.68% ]Bharti Airtel 425.45 [ 2.26% ]Bharat Heavy Ele 92.9 [ 1.81% ]Bharat Petroleum 430.1 [ 0.62% ]Britannia Ind. 4963.7 [ 2.12% ]Cairn India Ltd. 285.4 [ 0.90% ]Cipla 595.15 [ 0.90% ]Coal India Ltd. 310.55 [ -0.48% ]Colgate Palm. 1049.9 [ 0.46% ]Dabur India 329.05 [ 0.63% ]DLF Ltd. 225 [ 2.13% ]Dr. Reddy's Labs 2169.25 [ 2.26% ]GAIL (India) Ltd. 458.35 [ -1.63% ]Grasim Inds. 1133.75 [ 2.11% ]HCL Technologies 956.1 [ 1.60% ]HDFC 1824.05 [ 0.35% ]HDFC Bank 1879.8 [ 1.34% ]Hero MotoCorp 3498.65 [ 0.47% ]Hindustan Unilever L 1323 [ -0.16% ]Hindalco Indus. 246.55 [ 2.71% ]ICICI Bank 321.3 [ 1.04% ]IDFC L 52.95 [ 2.42% ]Indian Hotels Co 131.8 [ -0.53% ]IndusInd Bank 1642.9 [ 1.14% ]Infosys 1155.65 [ -0.42% ]ITC Ltd. 269.05 [ 0.71% ]Jindal St & Pwr 264.7 [ 5.37% ]Kotak Mahindra Bank 1079.85 [ 0.67% ]L&T 1302.35 [ 0.86% ]Lupin Ltd. 807.15 [ 0.73% ]Mahi. & Mahi 719.3 [ -0.22% ]Maruti Suzuki India 8705.3 [ 0.63% ]MTNL 23.65 [ -2.47% ]Nestle India 7582.5 [ 0.56% ]NIIT Ltd. 94.55 [ -0.89% ]NMDC Ltd. 130.5 [ 2.84% ]NTPC 162.8 [ 1.43% ]ONGC 190 [ 2.04% ]Punj. NationlBak 113.4 [ -1.09% ]Power Grid Corpo 193.25 [ 1.20% ]Reliance Inds. 934 [ 1.09% ]SBI 276.1 [ 1.28% ]Vedanta 337.5 [ 2.82% ]Shipping Corpn. 73.05 [ 0.14% ]Sun Pharma. 570.2 [ 5.17% ]Tata Chemicals 706.5 [ 1.28% ]Tata Global Beverage 270.8 [ 3.22% ]Tata Motors Ltd. 360.45 [ 0.53% ]Tata Steel 677.8 [ 6.26% ]Tata Power Co. 85.65 [ 0.71% ]Tata Consultancy 3076.9 [ 1.20% ]Tech Mahindra Ltd. 620.4 [ 3.03% ]UltraTech Cement 4115.75 [ 0.29% ]United Spirits 3237.5 [ 2.48% ]Wipro Ltd 294.15 [ 0.60% ]Zee Entertainment En 570.2 [ 0.65% ]

News Details

You can view in detail.
Dr. Reddy’s Lab’s arm to initiate Phase 2 trial of CA-170 13/09/2017 10:27

Dr. Reddy’s Laboratories Ltd. has said that Aurigene Discovery Technologies Limited, a wholly owned subsidiary of the company plans to initiate a Phase 2 trial of CA-170, a PDL1-VISTA inhibitor to be conducted at sites in India.

This was announced following the presentation of preliminary data from the initial 34 patients with cancer treated in the dose escalation stage of the Phase 1 trial of CA-170 at the European Society for Medical Oncology (ESMO) 2017 Congress by Aurigene’s collaborator and licensee of CA-170, Curis, Inc., a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer.

“The trial has been conducted in the U.S., South Korea and Spain. The Phase 2 trial is the result of the initial safety data and preliminary evidence of clinical benefit observed in the trial,” the company said in a filing to the Bombay Stock Exchange.

Meanwhile, shares of the company were trading at Rs 2197.05 apiece, up 1.49 per cent from the previous close at 10:33 hours on BSE.

LOAD MORE